-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Upgrades Neumora Therapeutics to Outperform, Raises Price Target to $7

Benzinga·12/01/2025 11:33:16
Listen to the news
RBC Capital analyst Brian Abrahams upgrades Neumora Therapeutics (NASDAQ:NMRA) from Sector Perform to Outperform and raises the price target from $4 to $7.